Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Colorectal Cancer
Interventions: LBH589; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Subarachnoid Hemorrhage, Cerebral Vasospasm, Hyponatremia
Interventions: HTS 3%, Standard fluid management; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Wound Healing
Interventions: TolaSure Topical Gel, Topical Vehicle Gel; Drug
Lead sponsor: BioMendics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Miami, Florida • College Station, Texas

Conditions: Adult Lymphoblastic Lymphoma
Interventions: Fludarabine, Total Body Irradiation; Drug · Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cobimetinib, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 13 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BCT197, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin

Conditions: Prostatic Neoplasms, Pelvic Nodal
Interventions: Enzalutamide, Leuprolide, Intensity-Modulated Radiation Therapy; Drug · Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Lentinan, Didanosine; Drug
Lead sponsor: AJI Pharma USA; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glabellar Lines
Interventions: OnabotulinumtoxinA X, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Glendale, Arizona • Los Angeles, California • Newport Beach, California + 15 more

Conditions: Brain Metastases From Solid Tumors
Interventions: Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3; Biological
Lead sponsor: T-MAXIMUM Pharmaceutical Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Musculoskeletal Complications, Pain
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 714
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: Taletrectinib; Drug
Lead sponsor: Megan Kruse, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Advanced Solid Tumors
Interventions: EMB-02; Biological
Lead sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Greenville, South Carolina

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more

Conditions: Alzheimer's Disease
Interventions: CPC-201; Drug
Lead sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Industry
Eligibility: 50 Years to 79 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Breast Cancer, Pain, Perioperative/Postoperative Complications
Interventions: therapeutic conventional surgery; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Carboplatin, Erlotinib, Erlotinib Hydrochloride, Paclitaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 96
States / cities: Castro Valley, California • Emeryville, California • Fremont, California + 68 more

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 16
States / cities: Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 12 more

Conditions: Atopic Dermatitis
Interventions: KHK4083, Placebo; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Huntington Beach, California • Irvine, California • Los Angeles, California + 10 more

Conditions: Pain, Cannabis, Opioid Use, Unspecified
Interventions: Within-subject test of blinded study medications; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Inavolisib, Ribociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Anaheim, California • Palo Alto, California • Jacksonville, Florida + 8 more

Conditions: Malignant Neoplasm
Interventions: MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota

Conditions: NSCLC Stage IV, NSCLC Stage IIIB
Interventions: Ipatasertib; Drug
Lead sponsor: Jun Zhang, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 2 more

Conditions: Advanced Melanoma
Interventions: Botensilimab, Balstilimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Scottsdale, Arizona • Fullerton, California • Santa Monica, California + 4 more

Search by objective public record fields.

Phase II Trial of LBH589 in Refractory Colorectal Cancer

Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

A Study of EMB-02 in Participants With Advanced Solid Tumors

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Enhancing Medication-based Analgesia in Humans

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma